July 2020 Vol 11, No 7

Telehealth continues to play a critical role in providing healthcare services to patients during the COVID-19 pandemic. In a webcast titled COVID-19: Impact on Telehealth, Rick Lee, Executive Chairman, Healthy Platforms and CancerLife, along with a panel of experts, discussed the benefits and ongoing challenges associated with the use of telemedicine and the far-reaching impact of this technology beyond the current crisis.
The federal government is an active participant in shaping healthcare policy and delivering care. The panelists in this session addressed the government’s response to COVID-19 and weighed in on some of the issues that their agencies frequently encountered as medical practices grapple with the new normal.
We are living in a time that is filled with multiple challenges. I want to bring to your attention that the Academy of Oncology Nurse & Patient Navigators (AONN+) has created a virtual toolkit of information for our membership regarding the COVID-19 pandemic.
At the 2020 virtual meeting of the American Association for Cancer Research (AACR), a group of oncologists working in different hot spots around the world gave a snapshot of wisdom gleaned from their experience thus far.
The authors advocate for nurse navigation services to guide patients through this challenging time in their lives.
On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic translocations.
Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at higher risk of relapse and require more aggressive adjuvant therapy.
Exploring second opinions allows patients to become more informed and secure in their choice of which treatment to pursue.
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma.
The first off-the-shelf chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with adult relapsed/ refractory T-cell acute lymphoblastic leukemia (T-ALL) who were treated with the universal CAR T-cell therapy known as GC027.
The combination of the checkpoint inhibitor durvalumab, the PARP inhibitor olaparib, and the taxane paclitaxel as neoadjuvant therapy improved pathological complete response (pCR) compared with physician’s choice of chemotherapy in high-risk HER2-negative stage II or III breast cancer.
The combination of the checkpoint inhibitor atezolizumab plus the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib improved progression-free survival (PFS) and lengthened duration of responses compared with the 2 targeted therapies plus placebo in newly diagnosed BRAF V600E/K–mutant advanced melanoma, according to results of the phase 3 IMspire150 trial presented at the 2020 virtual meeting of the American Association for Cancer Research.
The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce the launch of a national committee addressing community outreach, prevention, and early detection.

Results 1 - 13 of 13

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country